NCT02677493View on ClinicalTrials.gov

Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'

PHASE3CompletedINTERVENTIONAL
Enrollment

1,794

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

June 30, 2016

Conditions
Influenza
Interventions
BIOLOGICAL

IL-YANG Quadrivalent Influenza Vaccine

A single 0.5mL dose administrated as an intramuscular injection.

BIOLOGICAL

IL-YANG Flu Vaccine Prefilled Syringe

A single 0.5mL dose administrated as an intramuscular injection.

BIOLOGICAL

IL-YANG Trivalent Influenza Vaccine

A single 0.5mL dose administrated as an intramuscular injection.

All Listed Sponsors
lead

Il-Yang Pharm. Co., Ltd.

INDUSTRY

NCT02677493 - Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.' | Biotech Hunter | Biotech Hunter